Idorsia (IDIA) Panoramica del titolo
Idorsia Ltd, società biofarmaceutica, è impegnata nella scoperta, nello sviluppo e nella commercializzazione di farmaci per esigenze mediche insoddisfatte in Svizzera, Stati Uniti, Giappone, Europa e Canada. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 2/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
IDIA Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Idorsia Ltd
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | CHF 6.18 |
| Massimo di 52 settimane | CHF 7.56 |
| Minimo di 52 settimane | CHF 2.24 |
| Beta | 1.67 |
| Variazione di 1 mese | 36.24% |
| Variazione a 3 mesi | 68.48% |
| Variazione di 1 anno | 173.45% |
| Variazione a 3 anni | -10.82% |
| Variazione a 5 anni | -74.90% |
| Variazione dall'IPO | -54.73% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Jul 10
IDIA: Future CEO Transition And Debt Refinancing Will Test Equity Downside
Analysts recently lifted their price target on Idorsia to CHF 4.50 from CHF 4.00, citing updated assumptions for revenue growth, profit margins, discount rates and future P/E levels in their valuation work. What’s in the News for Idorsia Idorsia appointed Roland Wandeler, PhD, as Chief Executive Officer effective October 1, 2026.
Aggiornamento narrativa • Jun 26
IDIA: Pharmakon Debt Will Likely Constrain Long-Term Upside Potential
Analysts recently lifted their price target on Idorsia stock from CHF 4.00 to CHF 4.50, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What’s in the News for Idorsia Idorsia confirmed the closing of a senior secured term loan of up to CHF 250 million with funds managed by Pharmakon Advisors.Recent updates
Aggiornamento narrativa • Jul 10
IDIA: Future CEO Transition And Debt Refinancing Will Test Equity Downside
Analysts recently lifted their price target on Idorsia to CHF 4.50 from CHF 4.00, citing updated assumptions for revenue growth, profit margins, discount rates and future P/E levels in their valuation work. What’s in the News for Idorsia Idorsia appointed Roland Wandeler, PhD, as Chief Executive Officer effective October 1, 2026.Aggiornamento narrativa • Jun 26
IDIA: Pharmakon Debt Will Likely Constrain Long-Term Upside Potential
Analysts recently lifted their price target on Idorsia stock from CHF 4.00 to CHF 4.50, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What’s in the News for Idorsia Idorsia confirmed the closing of a senior secured term loan of up to CHF 250 million with funds managed by Pharmakon Advisors.
Aggiornamento narrativa • Jun 05
IDIA: Pediatric Sleep And Vaccine Pipeline Will Support Future Upside Despite Higher Costs
Analysts have lowered their price target on Idorsia to CHF 5, down from CHF 6. They cite reduced forward visibility and higher operating expenses as the main reasons for this adjustment.Aggiornamento narrativa • May 04
IDIA: Pediatric And Fabry Pipelines Will Support Future Upside Despite Higher Costs
Analysts have reduced their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the main reasons for the change. Analyst Commentary Bullish Takeaways Bullish analysts maintain a positive stance on the shares even after the price target move to CHF 5, which signals that they still see potential upside from current levels.Aggiornamento narrativa • Apr 18
IDIA: Fabry And Pediatric Programs Will Drive Future Upside Despite Higher Costs
Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent commentary points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern about execution risks and spending.Aggiornamento narrativa • Apr 04
IDIA: Fabry Pipeline Progress Will Continue To Drive Future Upside
Analysts have trimmed their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the key reasons for the reset. Analyst Commentary Bullish Takeaways Bullish analysts are still assigning upside potential to Idorsia shares even after the target reset to CHF 5, which signals that they see value at current levels despite near term headwinds.Aggiornamento narrativa • Mar 20
IDIA: Fabry And Resistant Hypertension Progress Will Continue To Drive Future Upside
Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent research points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern around execution and cost control.Aggiornamento narrativa • Mar 05
IDIA: Fabry And Resistant Hypertension Progress Will Likely Drive Future Upside
Analysts have revised their CHF price targets for Idorsia to reflect updated assumptions for discount rates, revenue growth, profit margins and future P/E. They are now presenting a more balanced view of the company’s risk and earnings potential.Aggiornamento narrativa • Feb 19
IDIA: Fabry And Hypertension Pipeline Advances Will Likely Drive Future Upside
Analysts have adjusted their CHF price target on Idorsia based on updated assumptions around discount rates, revenue, profit margins, and a higher expected future P/E multiple, resulting in a revised valuation framework in CHF terms. What's in the News Idorsia outlined an FDA-agreed Phase 3 registration program for lucerastat in Fabry disease, centered on kidney pathology and including a pivotal biopsy study plus a second trial comparing oral therapy with current standard-of-care to support a potential market authorization pathway (Key Developments).Aggiornamento narrativa • Feb 04
IDIA: Hypertension And Insomnia Pipeline Progress Will Likely Drive Future Upside
Analysts have trimmed their price target on Idorsia to reflect a slightly lower profit margin outlook and a higher assumed future P/E of 31.60x, while keeping their fair value estimate broadly unchanged. What's in the News Idorsia signed an exclusive license and supply agreement with EMS S.A. to bring QUVIVIQ (daridorexant) to patients across Latin America.Aggiornamento narrativa • Jan 21
IDIA: Hypertension And Insomnia Franchise Will Likely Drive Future Upside
Analysts have adjusted their price target on Idorsia slightly lower to reflect updated assumptions around fair value, a modestly higher discount rate, more conservative revenue growth expectations, a similar profit margin outlook, and a higher future P/E multiple. What's in the News Publication of Phase 3 MODIFY and open label extension data for lucerastat in Fabry disease, with results in Nature Communications highlighting sustained biomarker reductions and signals on renal and cardiac function in a small patient population.Aggiornamento narrativa • Jan 07
IDIA: Hypertension And Insomnia Assets Will Likely Drive Future Upside
Analysts have kept their price target for Idorsia broadly unchanged. They cite only small tweaks to inputs such as a slightly higher discount rate, steady revenue growth and profit margin assumptions, and a marginally adjusted future P/E multiple as the basis for their updated view.Articolo di analisi • Dec 22
Idorsia Ltd (VTX:IDIA) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Idorsia Ltd ( VTX:IDIA ) shares have had a really impressive month, gaining 28% after a shaky period beforehand. The...Aggiornamento narrativa • Dec 17
IDIA: Hypertension And Insomnia Portfolio Will Likely Deliver Upside From Current Levels
Analysts have raised their price target for Idorsia significantly, citing a higher fair value estimate of 5.0 dollars, stronger anticipated revenue growth, and an expectation of a materially higher future price to earnings multiple, partially offset by a slightly lower discount rate. What's in the News Idorsia reaffirmed 2025 guidance, targeting around CHF 130 million in QUVIVIQ net sales and a US-GAAP operating loss of about CHF 55 million for the global business, supported by approximately CHF 165 million EBIT from partnered activities (corporate guidance).Aggiornamento narrativa • Dec 03
IDIA: Hypertension And Insomnia Portfolio Will Likely Fail To Justify Current Price
Analysts have modestly raised their price target on Idorsia, citing a slightly lower perceived risk profile and a marginally stronger long term profit outlook that supports a small increase in fair value, now estimated at approximately 2.00. What's in the News Reaffirmed 2025 guidance, projecting QUVIVIQ net sales around CHF 130 million, partnered business US-GAAP EBIT of about CHF 165 million, and a global US-GAAP operating loss of roughly CHF 55 million, mainly driven by the amended Viatris deal (corporate guidance).Aggiornamento narrativa • Nov 19
IDIA: Limited Near-Term Upside Expected Despite Recent Price Reassessment
Narrative Update on Idorsia Analysts have raised their price target for Idorsia, doubling it from CHF 1 to CHF 2. This change is attributed to improved outlooks in key financial metrics, including a slightly lower discount rate and stable revenue growth projections.Articolo di analisi • Nov 07
Little Excitement Around Idorsia Ltd's (VTX:IDIA) Revenues As Shares Take 29% Pounding
The Idorsia Ltd ( VTX:IDIA ) share price has softened a substantial 29% over the previous 30 days, handing back much of...Aggiornamento narrativa • Nov 03
IDIA: Near-Term Risks Will Likely Limit Upside Despite Price Target Lift
Analysts have increased their price target for Idorsia by CHF 1.00 to CHF 2.00. They cite improved revenue growth projections and a more favorable future price-to-earnings outlook, despite a slightly higher discount rate and modestly lower profit margin expectations.Aggiornamento narrativa • Sep 23
Global Expansion And FDA Review Will Moderate Overvaluation
Despite a decline in revenue growth forecasts, the significant rise in Idorsia’s future P/E multiple underpins the sharp increase in its consensus analyst price target from CHF2.00 to CHF4.00. What's in the News Simcere Pharmaceuticals launched QUVIVIQ (daridorexant), Idorsia's dual orexin receptor antagonist for insomnia, in China, with approval highlighting its differentiated clinical profile and lack of psychotropic labeling.Articolo di analisi • Sep 14
Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry
Idorsia Ltd ( VTX:IDIA ) shares have continued their recent momentum with a 38% gain in the last month alone. The...Nuova narrativa • Sep 08
Global Expansion And FDA Review Will Moderate Overvaluation
Key Takeaways Market optimism for rapid revenue growth may be premature, with unvalidated access, uncertain drug uptake, and regulatory outcomes adding risk to earnings expectations. Longer-term valuation appears inflated by pipeline commercialization hopes, while rising costs and increasing pricing scrutiny threaten future margins and profitability.Articolo di analisi • Aug 24
New Forecasts: Here's What Analysts Think The Future Holds For Idorsia Ltd (VTX:IDIA)
Shareholders in Idorsia Ltd ( VTX:IDIA ) may be thrilled to learn that the covering analyst has just delivered a major...Articolo di analisi • Jul 19
There's Reason For Concern Over Idorsia Ltd's (VTX:IDIA) Massive 46% Price Jump
Despite an already strong run, Idorsia Ltd ( VTX:IDIA ) shares have been powering on, with a gain of 46% in the last...Articolo di analisi • Dec 19
Improved Revenues Required Before Idorsia Ltd (VTX:IDIA) Stock's 71% Jump Looks Justified
Idorsia Ltd ( VTX:IDIA ) shareholders are no doubt pleased to see that the share price has bounced 71% in the last...Articolo di analisi • Nov 06
One Idorsia Ltd (VTX:IDIA) Analyst Has Been Cutting Their Forecasts
The latest analyst coverage could presage a bad day for Idorsia Ltd ( VTX:IDIA ), with the covering analyst making...Articolo di analisi • Nov 04
Market Cool On Idorsia Ltd's (VTX:IDIA) Revenues Pushing Shares 33% Lower
To the annoyance of some shareholders, Idorsia Ltd ( VTX:IDIA ) shares are down a considerable 33% in the last month...Articolo di analisi • Sep 18
Take Care Before Jumping Onto Idorsia Ltd (VTX:IDIA) Even Though It's 25% Cheaper
The Idorsia Ltd ( VTX:IDIA ) share price has fared very poorly over the last month, falling by a substantial 25%. For...Rendimenti per gli azionisti
| IDIA | CH Biotechs | CH Mercato | |
|---|---|---|---|
| 7D | -5.6% | -3.7% | -0.5% |
| 1Y | 173.5% | 38.2% | 16.3% |
Ritorno vs Industria: IDIA ha superato il Swiss Biotechs che ha restituito 38.2 % nell'ultimo anno.
Rendimento vs Mercato: IDIA ha superato il mercato Swiss che ha restituito 16.3 % nell'ultimo anno.
Volatilità dei prezzi
| IDIA volatility | |
|---|---|
| IDIA Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.1% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di IDIA è stato volatile rispetto al mercato Swiss.
Volatilità nel tempo: La volatilità settimanale ( 11% ) di IDIA è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni Swiss.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2017 | 456 | Jean-Paul Clozel | www.idorsia.com |
Idorsia Ltd, società biofarmaceutica, è impegnata nella scoperta, nello sviluppo e nella commercializzazione di farmaci per esigenze mediche insoddisfatte in Svizzera, Stati Uniti, Giappone, Europa e Canada. L'azienda ha una pipeline di sviluppo clinico per diverse aree terapeutiche, quali SNC, cardiovascolare, disturbi immunologici e malattie orfane. L'azienda offre QUVIVIQ (daridorexant) per il trattamento dell'insonnia.
Idorsia Ltd Riepilogo dei fondamenti
| IDIA statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | CHF 1.58b |
| Utili (TTM) | -CHF 220.51m |
| Ricavi(TTM) | CHF 219.10m |
7.2x
Rapporto P/S-7.1x
Rapporto P/EIDIA è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| IDIA Conto economico (TTM) | |
|---|---|
| Ricavi | CHF 219.10m |
| Costo del fatturato | CHF 125.04m |
| Profitto lordo | CHF 94.06m |
| Altre spese | CHF 314.57m |
| Utili | -CHF 220.51m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Jul 30, 2026
| Utile per azione (EPS) | -0.86 |
| Margine lordo | 42.93% |
| Margine di profitto netto | -100.65% |
| Rapporto debito/patrimonio netto | -102.9% |
Come si è comportato IDIA nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/14 23:14 |
| Prezzo dell'azione a fine giornata | 2026/07/14 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Idorsia Ltd è coperta da 10 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Rosie Turner | Barclays |
| Alistair Campbell | Berenberg |
| Sachin Jain | BofA Global Research |